WeberJSO’DaySUrbaW. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol2008; 26: 5950–5956.
2.
HodiFSO’DaySJMcDermottDF. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med2010; 363: 711–723. [Erratum, N Engl J Med 2010; 363: 1290.]
3.
BotIBlankCUBoogerdW. Neurological immune-related adverse events of ipilimumab.Pract Neurol2013; 13: 278–280.
4.
LiaoBShroffSKamiya-MatsuokaC. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol2014; 16: 589–593.
